Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) (NCT07154706)
A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC). The study compares taletrectinib (study drug) versus placebo (sugar pill) in patients with ROS1-fusion positive stage IB, II, IIIA NSCLC. The study will evaluate if taletrectinib is better than placebo at preventing the participant's disease from coming back after the participant's lung tumor was removed.
Who can join: Review the eligibility criteria below.
Location: UCLA — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (33 Sites)
Showing the first 25 of 33 sites.
- UCLA — Los Angeles, California
- UCI Chao Family Comprehensive Cancer Center — Orange, California
- Georgetown University Medical Cener (GUMC) — Washington D.C., District of Columbia
- Advent Health — Orlando, Florida
- Saint Alphonsus Health System — Boise, Idaho
- Tulane Cancer Center — New Orleans, Louisiana
- Dana Farber Cancer Institute — Boston, Massachusetts
- Mayo Clinic — Rochester, Minnesota
- Memorial Sloan Kettering Cancer Center — New York, New York
- Sarah Cannon Research Institute (SCRI) - Texas Oncology-Central South — Austin, Texas
- MD Anderson — Houston, Texas
- Virginia Cancer Specialists — Fairfax, Virginia
- Princess Margaret Cancer Centre-University Health Network — Toronto, Ontario
- McGill University — Montreal, Quebec
- Peking University People's Hospital — Beijing, Beijing Municipality
- Beijing Cancer Hospital — Beijing, Beijing Municipality
- The First Affiliated Hospital of Guangzhou Medical University — Guangzhou, Guangdong
- Guangxi Medical University Cancer Hospital — Nanning, Guangxi
- Sun Yat-sen University Cancer Center — Guangzhou, Guangzhou
- The First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan
- Tongji Hospital Tongji Medical College of HUST — Wuhan, Hubei
- Nanjing Drum Tower Hospital — Nanjing, Jiangsu
- Nantong Tumor Hospital — Nantong, Jiangsu
- The First Affiliated Hospital of Nanchang University — Nanchang, Jiangxi
- The First Affiliated Hospital of Xi'an Jiaotong University — Xi'an, Shaanxi
📞 Contact the Study Coordinator
Phone: (310) 633-8400
Email: TinaTieu@mednet.ucla.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-small Cell Lung Cancer (NSCLC)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) — Oakland, California
- HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer — Santa Monica, California
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung — Tampa, Florida
- U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer — Duarte, California
- Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC — Duarte, California
- Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) — Birmingham, Alabama
Explore by condition: All Non-small Cell Lung Cancer (NSCLC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.